Literature DB >> 22134716

Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cells.

M Bar-Natan, E A Nelson, S R Walker, Y Kuang, R J Distel, D A Frank.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22134716     DOI： 10.1038/leu.2011.338

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  20 in total

1.  Loss of pleckstrin-2 reverts lethality and vascular occlusions in JAK2V617F-positive myeloproliferative neoplasms.

Authors:  Baobing Zhao; Yang Mei; Lan Cao; Jingxin Zhang; Ronen Sumagin; Jing Yang; Juehua Gao; Matthew J Schipma; Yanfeng Wang; Chelsea Thorsheim; Liang Zhao; Timothy Stalker; Brady Stein; Qiang Jeremy Wen; John D Crispino; Charles S Abrams; Peng Ji
Journal:  J Clin Invest       Date:  2017-11-20       Impact factor: 14.808

2.  NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells.

Authors:  Bruna Alves Fenerich; Jaqueline Cristina Fernandes; Ana Paula Nunes Rodrigues Alves; Juan Luiz Coelho-Silva; Renata Scopim-Ribeiro; Priscila Santos Scheucher; Christopher A Eide; Cristina E Tognon; Brian J Druker; Eduardo Magalhães Rego; João Agostinho Machado-Neto; Fabiola Traina
Journal:  Signal Transduct Target Ther       Date:  2020-01-24

3.  Aberrantly high expression of the CUB and zona pellucida-like domain-containing protein 1 (CUZD1) in mammary epithelium leads to breast tumorigenesis.

Authors:  Janelle Mapes; Lavanya Anandan; Quanxi Li; Alison Neff; Charles V Clevenger; Indrani C Bagchi; Milan K Bagchi
Journal:  J Biol Chem       Date:  2018-01-10       Impact factor: 5.157

4.  Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2.

Authors:  Suhu Liu; Sarah R Walker; Erik A Nelson; Robert Cerulli; Michael Xiang; Patricia A Toniolo; Jun Qi; Richard M Stone; Martha Wadleigh; James E Bradner; David A Frank
Journal:  Mol Cancer Ther       Date:  2014-01-16       Impact factor: 6.261

Review 5.  Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer.

Authors:  Sarah R Walker; Michael Xiang; David A Frank
Journal:  Mol Cell Endocrinol       Date:  2013-03-24       Impact factor: 4.102

6.  STAT5 outcompetes STAT3 to regulate the expression of the oncogenic transcriptional modulator BCL6.

Authors:  Sarah R Walker; Erik A Nelson; Jennifer E Yeh; Luca Pinello; Guo-Cheng Yuan; David A Frank
Journal:  Mol Cell Biol       Date:  2013-05-28       Impact factor: 4.272

7.  The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations.

Authors:  Erik A Nelson; Sarah R Walker; Michael Xiang; Ellen Weisberg; Michal Bar-Natan; Rosemary Barrett; Suiyang Liu; Surender Kharbanda; Amanda L Christie; Maria Nicolais; James D Griffin; Richard M Stone; Andrew L Kung; David A Frank
Journal:  Genes Cancer       Date:  2012-07

8.  STAT5 and prolactin participate in a positive autocrine feedback loop that promotes angiogenesis.

Authors:  Xinhai Yang; Kristy Meyer; Andreas Friedl
Journal:  J Biol Chem       Date:  2013-06-02       Impact factor: 5.157

Review 9.  Screening approaches to generating STAT inhibitors: Allowing the hits to identify the targets.

Authors:  Sarah R Walker; David A Frank
Journal:  JAKSTAT       Date:  2012-10-01

Review 10.  STAT signaling in the pathogenesis and treatment of myeloid malignancies.

Authors:  Michal Bar-Natan; Erik A Nelson; Michael Xiang; David A Frank
Journal:  JAKSTAT       Date:  2012-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.